Moloney Securities Asset Management LLC Has $1.23 Million Stock Position in Moderna, Inc. $MRNA

Moloney Securities Asset Management LLC cut its holdings in Moderna, Inc. (NASDAQ:MRNA) by 11.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 44,575 shares of the company’s stock after selling 5,575 shares during the period. Moloney Securities Asset Management LLC’s holdings in Moderna were worth $1,230,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. S Bank Fund Management Ltd bought a new stake in Moderna in the 1st quarter valued at about $25,000. TD Private Client Wealth LLC boosted its stake in shares of Moderna by 348.8% in the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after buying an additional 743 shares during the period. SVB Wealth LLC acquired a new stake in Moderna during the first quarter worth approximately $28,000. Whittier Trust Co. bought a new position in Moderna during the 2nd quarter worth $28,000. Finally, CX Institutional raised its holdings in Moderna by 1,129.8% in the 2nd quarter. CX Institutional now owns 1,033 shares of the company’s stock valued at $29,000 after acquiring an additional 949 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Up 1.9%

Shares of MRNA stock opened at $26.74 on Friday. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $57.69. The stock’s fifty day simple moving average is $25.94 and its 200 day simple moving average is $27.13. The firm has a market capitalization of $10.44 billion, a P/E ratio of -3.55 and a beta of 2.01.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The business’s quarterly revenue was down 41.1% on a year-over-year basis. During the same period last year, the company earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on MRNA. Weiss Ratings restated a “sell (e+)” rating on shares of Moderna in a research report on Wednesday, October 8th. Morgan Stanley boosted their target price on shares of Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a research report on Friday, October 10th. Evercore ISI set a $32.00 price target on shares of Moderna in a report on Friday, August 1st. Barclays decreased their price objective on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a research note on Monday, August 4th. Finally, UBS Group cut their target price on Moderna from $70.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $36.86.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.